REMS.

A required FDA safety programme attached to certain higher-risk drugs.

REMS stands for Risk Evaluation and Mitigation Strategy, a programme the United States Food and Drug Administration can require for a drug whose benefits are judged to outweigh its risks only if specific safeguards are in place. A REMS can range from a mandatory patient counselling document to substantially more restrictive elements: certification requirements for prescribers or pharmacies, enrolment registries, mandatory monitoring or laboratory testing before dispensing, and controlled distribution channels. It is imposed by the regulator as a condition of approval or of continued marketing, not adopted voluntarily. The concept is useful in peptide reading as a reference point for what managed risk actually looks like in a regulated setting. When a drug carries a serious, identifiable, and preventable hazard, the system's response is a structured programme with named responsibilities and documented checks, not a warning line on a website. That contrast is the point worth taking away. Compounds distributed as research-use-only sit entirely outside this framework, which does not mean they carry no comparable risks; it means no regulator has assessed them and no mitigation structure exists. A drug carrying a REMS has been examined closely enough for its risks to be characterised, which is more scrutiny than an unregulated compound has received, not less.